Development of Breast Carcinoma in Relation to the Intrinsic Subtype

[1]  B. Calhoun,et al.  Mucocele‐like lesions diagnosed on breast core biopsy: Low risk of upgrade and subsequent carcinoma , 2018, The breast journal.

[2]  B. Calhoun,et al.  Breast cancer risk associated with atypical hyperplasia and lobular carcinoma in situ initially diagnosed on core‐needle biopsy , 2018, Cancer.

[3]  L. Newman,et al.  Association Between Benign Breast Disease in African American and White American Women and Subsequent Triple-Negative Breast Cancer , 2017, JAMA oncology.

[4]  Andrew H. Beck,et al.  Expression of estrogen receptor, progesterone receptor, and Ki67 in normal breast tissue in relation to subsequent risk of breast cancer , 2016, npj Breast Cancer.

[5]  W. Ismail,et al.  Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast. , 2016, Asian Pacific journal of cancer prevention : APJCP.

[6]  C. Coutant,et al.  Atypical epithelial hyperplasia of the breast: state of the art , 2016, Expert review of anticancer therapy.

[7]  R. Vierkant,et al.  Mucocele-like lesions of the breast: a clinical outcome and histologic analysis of 102 cases. , 2016, Human pathology.

[8]  G. Colditz,et al.  Breast cancer risk by extent and type of atypical hyperplasia: An update from the Nurses' Health Studies , 2016, Cancer.

[9]  Anthony J. Guidi,et al.  Breast Cancer Risk and Follow-up Recommendations for Young Women Diagnosed with Atypical Hyperplasia and Lobular Carcinoma In Situ (LCIS) , 2015, Annals of Surgical Oncology.

[10]  Karthik Ghosh,et al.  Flat epithelial atypia and risk of breast cancer: A Mayo cohort study , 2015, Cancer.

[11]  R. Gelber,et al.  Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  G. Colditz,et al.  Breast cancer risk associated with benign breast disease: systematic review and meta-analysis , 2015, Breast Cancer Research and Treatment.

[13]  Vandana G. Abramson,et al.  New Strategies for Triple-Negative Breast Cancer—Deciphering the Heterogeneity , 2014, Clinical Cancer Research.

[14]  D. Radisky,et al.  Benign Breast Disease and the Risk of Subsequent Breast Cancer in African American Women , 2012, Cancer Prevention Research.

[15]  W. Dupont,et al.  Clinicopathologic characteristics of carcinomas that develop after a biopsy containing columnar cell lesions , 2012, Cancer.

[16]  D. Sgroi,et al.  The molecular pathology of breast cancer progression , 2011, The Journal of pathology.

[17]  Charles M. Perou,et al.  Deconstructing the molecular portraits of breast cancer , 2010, Molecular oncology.

[18]  Charles M Perou,et al.  Molecular stratification of triple-negative breast cancers. , 2010, The oncologist.

[19]  N. Kanomata,et al.  Molecular morphological approach to the pathological study of development and advancement of human breast cancer , 2010, Medical Molecular Morphology.

[20]  J. Reis-Filho,et al.  Breast cancer precursors revisited: molecular features and progression pathways , 2010, Histopathology.

[21]  K. Aronson,et al.  Estrogen and progesterone receptor levels in nonneoplastic breast epithelium of breast cancer cases versus benign breast biopsy controls , 2008, BMC Cancer.

[22]  Suzanne M. Brandt,et al.  The "Rosen Triad": tubular carcinoma, lobular carcinoma in situ, and columnar cell lesions. , 2008, Advances in anatomic pathology.

[23]  A. Tutt,et al.  Triple negative tumours: a critical review , 2007, Histopathology.

[24]  Marc Tischkowitz,et al.  Use of immunohistochemical markers can refine prognosis in triple negative breast cancer , 2007, BMC Cancer.

[25]  Judith Abrams,et al.  Breast Cancer Incidence in a Cohort of Women with Benign Breast Disease from a Multiethnic, Primary Health Care Population , 2007, The breast journal.

[26]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[27]  R. Severson,et al.  Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Norman Wolmark,et al.  Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project , 2004, Cancer.

[29]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[32]  W D Dupont,et al.  Risk factors for breast cancer in women with proliferative breast disease. , 1985, The New England journal of medicine.

[33]  T. Kinoshita,et al.  The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. , 2007, Breast.

[34]  Ian O Ellis,et al.  Prognostic markers in triple‐negative breast cancer , 2007, Cancer.